Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

彭布罗利珠单抗 医学 安慰剂 人口 肿瘤科 内科学 中止 临床研究阶段 黑色素瘤 临床试验 免疫疗法 癌症 癌症研究 病理 环境卫生 替代医学
作者
Georgina Venetia Long,Reinhard Dummer,Omid Hamid,Thomas Frank Gajewski,Christian Caglevic,Stéphane Dalle,Ana Maria Arance,Matteo Salvatore Carlino,Jean‐Jacques Grob,Tae Min Kim,Лев Вадимович Демидов,Caroline Robert,James Larkin,James Robert Anderson,Janet E. Maleski,Mark Jones,Scott J. Diede,Tara C. Mitchell
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:20 (8): 1083-1097 被引量:1036
标识
DOI:10.1016/s1470-2045(19)30274-8
摘要

Immunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma. In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab versus placebo plus pembrolizumab.In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening. Patients were stratified by PD-L1 expression and BRAFV600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg intravenously every 3 weeks or placebo plus pembrolizumab for up to 2 years. We used block randomisation with a block size of four in each stratum. Primary endpoints were progression-free survival and overall survival in the intention-to-treat population. The safety analysis population included randomly assigned patients who received at least one dose of study treatment. The study was stopped after the second interim analysis; follow-up for safety is ongoing. This study is registered with ClinicalTrials.gov, number NCT02752074.Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352). Median follow-up was 12·4 months (IQR 10·3-14·5). No significant differences were found between the treatment groups for progression-free survival (median 4·7 months, 95% CI 2·9-6·8, for epacadostat plus pembrolizumab vs 4·9 months, 2·9-6·8, for placebo plus pembrolizumab; hazard ratio [HR] 1·00, 95% CI 0·83-1·21; one-sided p=0·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1·13, 0·86-1·49; one-sided p=0·81). The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab. Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab. There were no treatment-related deaths in either treatment group.Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival or overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastatic melanoma. The usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy activity in cancer remains uncertain.Incyte Corporation, in collaboration with Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
科研通AI65的应助被qwer采纳,获得10
刚刚
1秒前
1秒前
老实幻姬完成签到,获得积分10
1秒前
虚幻百川完成签到,获得积分0
2秒前
虚拟的水壶完成签到,获得积分10
2秒前
2秒前
momo123完成签到,获得积分10
3秒前
3秒前
123完成签到,获得积分20
3秒前
刘欣媛发布了新的文献求助10
3秒前
4秒前
hh完成签到,获得积分10
4秒前
whisper发布了新的文献求助10
4秒前
Echor完成签到,获得积分10
5秒前
5秒前
5秒前
无极微光的应助被O耶采纳,获得20
5秒前
文静的摩托完成签到,获得积分10
5秒前
终梦的应助被momo123采纳,获得10
6秒前
7秒前
虎虎完成签到,获得积分10
7秒前
7秒前
8秒前
我是老大的应助被假装有昵称采纳,获得10
8秒前
英俊的铭的应助被十二点的茶采纳,获得10
9秒前
9秒前
9秒前
9秒前
9秒前
9秒前
冷酷以山发布了新的文献求助100
10秒前
10秒前
我有颗糖完成签到,获得积分20
10秒前
星1993发布了新的文献求助10
10秒前
书包王完成签到,获得积分10
11秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482